- Mr. Greg McKee, CEO of Tryp Therapeutics, appeared on The Dealmaker Podcast to share insights on the company and the psychedelics industry
- During the interview, he discussed the potential of psychedelics in the treatment of PTSD and other mental disorders
- Greg also shared the challenges that the industry is facing currently, mostly to do with legislation
- McKee also shared how people can help the company and the industry by pushing for the decriminalization of psychedelics and taking part in clinical trials
On August 2, 2021, the Dealmaker Podcast posted an interview with Greg McKee, the Chief Executive Officer (“CEO”) of
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF). The show, hosted by Oren Klaff, sought to give the audience an understanding of Tryp Therapeutics’ operations, along with Mr. McKee’s personal story on how he ended up as the CEO of the company (
https://ibn.fm/Puuse). It offered some great insights into the future of the psychedelics space, along with what ordinary people can do to take the industry to the next level.
When discussing what Tryp Therapeutics is all about, Mr. McKee acknowledged the current boom in the psychedelics space and the potential that these substances…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at
https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates
PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit
https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:
https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW?
Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the
InvestorBrandNetwork.